|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO EXP |
3-aminobenzamide promotes the reaction [Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]]; 3-aminobenzamide promotes the reaction [Alitretinoin results in increased expression of ABCA1 mRNA]; Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]; Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 protein]; T0901317 promotes the reaction [Alitretinoin results in increased expression of ABCA1 mRNA] [22-hydroxycholesterol co-treated with Alitretinoin] results in increased expression of ABCA1 mRNA; [22-hydroxycholesterol co-treated with Alitretinoin] results in increased expression of ABCA1 protein [22-hydroxycholesterol co-treated with Alitretinoin] results in increased expression of ABCA1 protein; [25-hydroxycholesterol co-treated with Alitretinoin] results in increased expression of ABCA1 protein; [Alitretinoin co-treated with 22-hydroxycholesterol] results in increased expression of ABCA1 mRNA; [Alitretinoin co-treated with 22-hydroxycholesterol] results in increased expression of ABCA1 protein; Arsenic Trioxide inhibits the reaction [[Alitretinoin co-treated with 22-hydroxycholesterol] results in increased expression of ABCA1 mRNA]; Arsenic Trioxide inhibits the reaction [[Alitretinoin co-treated with 22-hydroxycholesterol] results in increased expression of ABCA1 protein] |
CTD |
PMID:16023994 PMID:16184197 PMID:17478430 PMID:27026705 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Alitretinoin results in increased expression of ABCC3 mRNA |
CTD |
PMID:15824121 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions increases expression |
ISO |
RARA protein promotes the reaction [Alitretinoin results in increased expression of ABCC6 mRNA] |
CTD |
PMID:17045963 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
increases expression |
EXP |
Alitretinoin results in increased expression of ABCD3 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions increases expression |
ISO |
[T0901317 co-treated with Alitretinoin] results in increased expression of ABCG1 mRNA Alitretinoin results in increased expression of ABCG1 mRNA |
CTD |
PMID:16024918 PMID:16730733 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression |
EXP |
Alitretinoin results in increased expression of ACOT2 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
Alitretinoin results in increased expression of ACTA2 mRNA 15-deoxyprostaglandin J2 inhibits the reaction [Alitretinoin results in increased expression of ACTA2 mRNA]; Alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
decreases expression |
EXP |
Alitretinoin results in decreased expression of ACTG2 protein |
CTD |
PMID:16043492 |
|
NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions |
ISO |
[25-hydroxycholesterol co-treated with Alitretinoin] results in decreased expression of ADIPOR1 mRNA |
CTD |
PMID:16023994 |
|
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
decreases expression |
EXP |
Alitretinoin results in decreased expression of AHSG mRNA |
CTD |
PMID:16648578 |
|
NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Aip |
aryl-hydrocarbon receptor-interacting protein |
decreases expression |
ISO |
Alitretinoin results in decreased expression of AIP mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 1:201,408,002...201,419,220
Ensembl chr 1:201,407,288...201,419,122
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation increases phosphorylation multiple interactions |
ISO EXP |
Alitretinoin results in decreased phosphorylation of AKT1 protein Alitretinoin results in increased phosphorylation of AKT1 protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16288212 PMID:16340750 PMID:16611854 PMID:18063688 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of ANXA1 protein |
CTD |
PMID:28886987 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of ANXA2 protein |
CTD |
PMID:28886987 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of ANXA5 protein |
CTD |
PMID:28886987 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apoa2 |
apolipoprotein A2 |
increases expression multiple interactions |
ISO |
Alitretinoin results in increased expression of APOA2 mRNA RXRA promotes the reaction [Alitretinoin results in increased expression of APOA2 mRNA] |
CTD |
PMID:8668150 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [Flurbiprofen results in decreased secretion of APP protein] |
CTD |
PMID:19659691 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arpc1b |
actin related protein 2/3 complex, subunit 1B |
increases expression |
EXP |
Alitretinoin results in increased expression of ARPC1B mRNA |
CTD |
PMID:16648578 |
|
NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of ATP1B1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Alitretinoin results in increased expression of BAX; Alitretinoin results in increased expression of BAX protein seocalcitol inhibits the reaction [Alitretinoin results in increased expression of BAX protein] |
CTD |
PMID:12189556 PMID:16109544 PMID:16340750 PMID:16909596 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression decreases response to substance |
ISO |
Alitretinoin results in decreased expression of BCL2; Alitretinoin results in decreased expression of BCL2 protein BCL2 protein results in decreased susceptibility to Alitretinoin |
CTD |
PMID:12189556 PMID:16109544 PMID:16909596 PMID:17077328 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
seocalcitol inhibits the reaction [Alitretinoin results in increased expression of BCL2L11 protein] |
CTD |
PMID:16340750 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bco1 |
beta-carotene oxygenase 1 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of BCO1 mRNA |
CTD |
PMID:16699835 |
|
NCBI chr19:45,149,250...45,186,102
Ensembl chr19:45,149,265...45,186,101
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions decreases expression |
ISO |
[Calcitriol co-treated with Alitretinoin] results in increased expression of BGLAP mRNA; [Calcitriol co-treated with Alitretinoin] results in increased secretion of BGLAP protein; [KH 1060 co-treated with Alitretinoin] results in increased expression of BGLAP mRNA; [KH 1060 co-treated with Alitretinoin] results in increased secretion of BGLAP protein; Alitretinoin promotes the reaction [Calcitriol results in increased expression of BGLAP mRNA]; Alitretinoin promotes the reaction [Calcitriol results in increased secretion of BGLAP protein]; Alitretinoin promotes the reaction [KH 1060 results in increased expression of BGLAP mRNA]; Alitretinoin promotes the reaction [KH 1060 results in increased secretion of BGLAP protein]; Alitretinoin promotes the reaction [RXRB protein binds to BGLAP gene]; Alitretinoin promotes the reaction [VDR protein binds to BGLAP gene] Alitretinoin results in decreased expression of BGLAP mRNA |
CTD |
PMID:12898515 PMID:16392701 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
increases expression |
EXP |
Alitretinoin results in increased expression of CAMK2G mRNA |
CTD |
PMID:16648578 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
CAMK4 protein promotes the reaction [Alitretinoin results in increased activity of RARA protein] |
CTD |
PMID:15773917 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Capn1 |
calpain 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CAPN1 mRNA |
CTD |
PMID:17460283 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CAPN2 mRNA |
CTD |
PMID:17460283 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions increases expression |
ISO |
[Alitretinoin co-treated with seocalcitol] results in increased expression of CA2 protein Alitretinoin results in increased expression of CA2 protein |
CTD |
PMID:16340750 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO EXP |
Alitretinoin results in increased expression of CASP3; Alitretinoin results in increased expression of CASP3 protein [T0901317 co-treated with Alitretinoin] promotes the reaction [Palmitic Acid results in increased activity of CASP3 protein] |
CTD |
PMID:16109544 PMID:16909596 PMID:17194744 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
EXP |
[T0901317 co-treated with Alitretinoin] promotes the reaction [Palmitic Acid results in increased activity of CASP7 protein] |
CTD |
PMID:17194744 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Alitretinoin results in increased activity of CASP8 protein |
CTD |
PMID:16449964 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cbx3 |
chromobox 3 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CBX3 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[22-hydroxycholesterol co-treated with Alitretinoin] inhibits the reaction [IFNG promotes the reaction [STAT1 protein binds to CCL2 promoter]] |
CTD |
PMID:21268089 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in increased expression of CCNA2 protein] |
CTD |
PMID:11348869 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CCND3 protein |
CTD |
PMID:16273314 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
decreases expression multiple interactions |
ISO |
Alitretinoin results in decreased expression of CCR2 mRNA; Alitretinoin results in decreased expression of CCR2 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Alitretinoin results in decreased expression of CCR2 mRNA] |
CTD |
PMID:16712875 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr3 |
C-C motif chemokine receptor 3 |
increases expression |
ISO |
Alitretinoin results in increased expression of CCR3 mRNA |
CTD |
PMID:16712875 |
|
NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
increases expression decreases expression |
ISO |
Alitretinoin results in increased expression of CCR7 protein Alitretinoin results in decreased expression of CCR7 protein |
CTD |
PMID:17475839 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd36 |
CD36 molecule |
decreases expression multiple interactions |
ISO |
Alitretinoin results in decreased expression of CD36 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Alitretinoin results in decreased expression of CD36 protein]; [Alitretinoin co-treated with Rosiglitazone] results in increased expression of CD36 protein; HX 630 inhibits the reaction [Alitretinoin results in decreased expression of CD36 protein] |
CTD |
PMID:17475839 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd37 |
CD37 molecule |
increases expression |
EXP |
Alitretinoin results in increased expression of CD37 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648
|
|
G |
Cd38 |
CD38 molecule |
increases expression multiple interactions |
ISO |
Alitretinoin results in increased expression of CD38 mRNA Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of CD38 mRNA]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of CD38 mRNA]] |
CTD |
PMID:15964820 PMID:21393419 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd80 |
Cd80 molecule |
decreases expression multiple interactions |
ISO |
Alitretinoin results in decreased expression of CD80 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Alitretinoin results in decreased expression of CD80 protein]; [Alitretinoin co-treated with Rosiglitazone] results in decreased expression of CD80 protein; HX 630 inhibits the reaction [Alitretinoin results in decreased expression of CD80 protein] |
CTD |
PMID:17475839 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd83 |
CD83 molecule |
increases expression |
ISO |
Alitretinoin results in increased expression of CD83 protein |
CTD |
PMID:17475839 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
increases expression multiple interactions |
ISO |
Alitretinoin results in increased expression of CD86 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Alitretinoin results in increased expression of CD86 protein]; [Alitretinoin co-treated with Rosiglitazone] results in increased expression of CD86 protein; HX 630 inhibits the reaction [Alitretinoin results in increased expression of CD86 protein] |
CTD |
PMID:17475839 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdh1 |
cadherin 1 |
affects expression |
ISO |
Alitretinoin affects the expression of CDH1 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CDH2 protein |
CTD |
PMID:36805303 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CDKN1A protein |
CTD |
PMID:16340750 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases stability multiple interactions increases expression |
ISO |
Alitretinoin results in increased stability of CDKN1B protein Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in decreased expression of CDKN1B protein]; seocalcitol inhibits the reaction [Alitretinoin results in increased expression of CDKN1B protein] |
CTD |
PMID:11348869 PMID:16340750 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CDKN1C mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
EXP |
[9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] results in increased activity of CEBPB protein |
CTD |
PMID:15150131 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Chat |
choline O-acetyltransferase |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CHAT protein |
CTD |
PMID:36805303 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Ciao1 |
cytosolic iron-sulfur assembly component 1 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of CIAO1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 3:114,458,671...114,465,928
Ensembl chr 3:114,458,655...114,467,009
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
increases expression |
ISO |
Alitretinoin results in increased expression of CIITA mRNA |
CTD |
PMID:17229644 |
|
NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions increases expression |
EXP |
15-deoxyprostaglandin J2 inhibits the reaction [Alitretinoin results in increased expression of CNN1 mRNA]; Alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
decreases expression |
EXP |
Alitretinoin results in decreased expression of COL12A1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
|
|
G |
Col17a1 |
collagen type XVII alpha 1 chain |
decreases expression |
ISO |
Alitretinoin results in decreased expression of COL17A1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 1:246,530,589...246,577,559
Ensembl chr 1:246,531,367...246,577,632
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Alitretinoin results in increased expression of COL1A1 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression |
EXP |
Alitretinoin results in increased expression of COL1A2 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
increases expression |
ISO |
Alitretinoin results in increased expression of COL4A2 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
decreases expression |
ISO |
Alitretinoin results in decreased expression of COL6A1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col8a2 |
collagen type VIII alpha 2 chain |
increases expression |
ISO |
Alitretinoin results in increased expression of COL8A2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 5:138,586,201...138,613,627
Ensembl chr 5:138,585,999...138,612,850
|
|
G |
Coro1b |
coronin 1B |
increases expression |
EXP |
Alitretinoin results in increased expression of CORO1B mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 1:201,442,977...201,448,416
Ensembl chr 1:201,443,014...201,448,416
|
|
G |
Crabp1 |
cellular retinoic acid binding protein 1 |
decreases response to substance |
ISO |
CRABP1 protein results in decreased susceptibility to Alitretinoin |
CTD |
PMID:16254461 |
|
NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO EXP |
Alitretinoin results in increased expression of CRABP2 mRNA Alitretinoin analog results in increased expression of CRABP2 mRNA; Alitretinoin results in increased expression of CRABP2 mRNA |
CTD |
PMID:11214822 PMID:16339527 PMID:16946489 PMID:17034753 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation |
ISO |
Alitretinoin results in increased phosphorylation of CREB1 protein |
CTD |
PMID:16280361 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crot |
carnitine O-octanoyltransferase |
increases expression |
EXP |
Alitretinoin results in increased expression of CROT mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CXCL1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of CXCL14 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of CXCL1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions decreases expression increases expression |
EXP ISO |
Alitretinoin promotes the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CYP19A1 mRNA] Alitretinoin results in decreased expression of CYP19A1 mRNA Alitretinoin results in increased expression of CYP19A1 mRNA [Alitretinoin binds to and results in increased activity of RXRA protein] which results in increased expression of CYP19A1 protein; Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Alitretinoin inhibits the reaction [NR5A2 protein results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:12706301 PMID:15941851 PMID:16357189 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of CYP26A1 mRNA |
CTD |
PMID:16194896 PMID:16688765 PMID:36805303 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp26c1 |
cytochrome P450, family 26, subfamily C, polypeptide 1 |
multiple interactions increases expression increases metabolic processing |
ISO |
Alitretinoin inhibits the reaction [CYP26C1 protein binds to and results in increased metabolism of Tretinoin]; CYP26C1 protein binds to and results in increased metabolism of Alitretinoin; Ketoconazole inhibits the reaction [CYP26C1 protein results in increased metabolism of Alitretinoin] Alitretinoin results in increased expression of CYP26C1 mRNA CYP26C1 results in increased metabolism of Alitretinoin |
CTD |
PMID:14532297 PMID:21906690 |
|
NCBI chr 1:235,458,961...235,468,433
Ensembl chr 1:235,459,356...235,466,842
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression decreases expression multiple interactions |
ISO |
Alitretinoin results in increased expression of CYP27A1 mRNA Alitretinoin results in decreased expression of CYP27A1 mRNA Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of CYP27A1 mRNA]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of CYP27A1 mRNA]] |
CTD |
PMID:15964820 PMID:15982314 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
RXRA protein affects the reaction [Alitretinoin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:31312845 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases activity multiple interactions |
ISO |
Alitretinoin results in increased activity of CYP3A4 protein 1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [Alitretinoin promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter]]; Alitretinoin promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter]]; Alitretinoin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Alitretinoin promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter] |
CTD |
PMID:16632523 PMID:19686701 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4f40 |
cytochrome P450, family 4, subfamily f, polypeptide 40 |
multiple interactions decreases expression |
ISO |
Alitretinoin inhibits the reaction [TNF protein results in increased expression of CYP4F11 mRNA] Alitretinoin results in decreased expression of CYP4F11 mRNA; Alitretinoin results in decreased expression of CYP4F11 protein |
CTD |
PMID:19812349 |
|
NCBI chr 7:11,691,648...11,707,437
Ensembl chr 7:11,692,086...11,706,229
|
|
G |
Dcx |
doublecortin |
decreases expression |
ISO |
Alitretinoin results in decreased expression of DCX mRNA |
CTD |
PMID:36805303 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
increases expression |
ISO |
Alitretinoin results in increased expression of DHRS9 mRNA |
CTD |
PMID:11304534 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of DIO1 mRNA |
CTD |
PMID:36805303 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of DIO2 mRNA |
CTD |
PMID:36805303 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases activity |
ISO |
Alitretinoin results in increased activity of DIO3 protein |
CTD |
PMID:16935842 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Arsenicals co-treated with Alitretinoin] results in increased expression of DNMT1 mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT1 mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
ISO |
[Arsenicals co-treated with Alitretinoin] results in increased expression of DNMT3A mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT3A mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dsc1 |
desmocollin 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of DSC1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr18:11,499,936...11,556,801
Ensembl chr18:11,502,003...11,528,494
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
Alitretinoin results in increased expression of DUSP10 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp11 |
dual specificity phosphatase 11 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of DUSP11 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 4:118,367,673...118,385,183
Ensembl chr 4:118,368,053...118,385,181
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Alitretinoin results in decreased expression of EGFR mRNA |
CTD |
PMID:15982314 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp2 |
eukaryotic translation initiation factor 4E binding protein 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of EIF4EBP2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr20:29,379,444...29,400,110
Ensembl chr20:29,382,668...29,399,946
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of EMP1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO EXP |
Alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA] Melatonin promotes the reaction [Alitretinoin results in decreased expression of ESR1 mRNA] |
CTD |
PMID:16051031 PMID:19340624 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR2 mRNA] |
CTD |
PMID:19340624 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of FABP5 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fabp7 |
fatty acid binding protein 7 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of FABP7 protein |
CTD |
PMID:36805303 |
|
NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880
|
|
G |
Fam3c |
FAM3 metabolism regulating signaling molecule C |
increases expression |
ISO |
Alitretinoin results in increased expression of FAM3C mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 4:50,839,929...50,887,276
Ensembl chr 4:50,838,818...50,888,078
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression increases expression |
ISO |
Alitretinoin results in decreased expression of FAS mRNA Alitretinoin results in increased expression of FAS mRNA |
CTD |
PMID:16712844 PMID:17034753 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Alitretinoin results in decreased expression of FASN mRNA |
CTD |
PMID:15982314 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
decreases expression |
ISO |
Alitretinoin results in decreased expression of FASTK mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
EXP |
Alitretinoin results in increased expression of FDFT1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of FGF1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression multiple interactions |
EXP |
Alitretinoin results in increased expression of FHL1 mRNA 15-deoxyprostaglandin J2 inhibits the reaction [Alitretinoin results in increased expression of FHL1 mRNA]; Alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Flg |
filaggrin |
decreases expression |
ISO |
Alitretinoin results in decreased expression of FLG mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Fn1 |
fibronectin 1 |
increases expression decreases expression |
EXP ISO |
Alitretinoin results in increased expression of FN1 mRNA Alitretinoin results in decreased expression of FN1 mRNA; Alitretinoin results in decreased expression of FN1 protein |
CTD |
PMID:11139446 PMID:16648578 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxa1 |
forkhead box A1 |
increases expression |
ISO |
Alitretinoin results in increased expression of FOXA1 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
ISO |
Alitretinoin results in increased expression of G6PD mRNA |
CTD |
PMID:15982314 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
ISO |
Alitretinoin results in decreased expression of GAPDH protein |
CTD |
PMID:28886987 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gata6 |
GATA binding protein 6 |
increases expression |
ISO |
Alitretinoin results in increased expression of GATA6 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gba1 |
glucosylceramidase beta 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of GBA1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263
|
|
G |
Gck |
glucokinase |
decreases expression decreases activity |
ISO EXP |
Alitretinoin results in decreased expression of GCK mRNA Alitretinoin results in decreased activity of GCK protein |
CTD |
PMID:21115832 PMID:21670153 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Alitretinoin results in increased expression of GDF15 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdf2 |
growth differentiation factor 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of GDF2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr16:9,255,430...9,261,429
Ensembl chr16:9,255,430...9,261,429
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
Alitretinoin results in increased expression of GFAP mRNA |
CTD |
PMID:36805303 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gh1 |
growth hormone 1 |
increases expression multiple interactions |
EXP |
Alitretinoin results in increased expression of GH1 mRNA Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]; Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]] |
CTD |
PMID:10720163 PMID:15240998 PMID:17090972 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
EXP |
Alitretinoin promotes the reaction [Dexamethasone results in increased expression of GHRH mRNA] |
CTD |
PMID:17090972 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Glul |
glutamate-ammonia ligase |
increases expression |
ISO |
Alitretinoin results in increased expression of GLUL mRNA |
CTD |
PMID:15982314 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Alitretinoin results in increased expression of GPX2 mRNA |
CTD |
PMID:15623509 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Grb7 |
growth factor receptor bound protein 7 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of GRB7 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr10:83,443,387...83,453,057
Ensembl chr10:83,444,004...83,453,052
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions increases expression |
EXP |
[9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] promotes the reaction [[PPARG protein binds to RXRA protein] which binds to GSTA2 promoter]; [9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] results in increased expression of GSTA2 mRNA; [9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] results in increased expression of GSTA2 protein; [Pioglitazone co-treated with Alitretinoin] results in increased expression of GSTA2 protein; [Rosiglitazone co-treated with Alitretinoin] results in increased expression of GSTA2 protein; [Troglitazone co-treated with Alitretinoin] results in increased expression of GSTA2 protein Alitretinoin results in increased expression of GSTA2 protein |
CTD |
PMID:15150131 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of GSTM1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
H3f4 |
H3.4 histone, cluster member |
multiple interactions |
ISO |
[Alitretinoin co-treated with Dimethyl Sulfoxide] promotes the reaction [H3-4 protein modified form binds to TGM2 gene]; Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased acetylation of H3-4 protein] |
CTD |
PMID:15964820 |
|
NCBI chr10:43,740,702...43,741,262
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Alitretinoin results in increased expression of HBEGF mRNA |
CTD |
PMID:15982314 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hgf |
hepatocyte growth factor |
decreases expression decreases secretion increases expression increases secretion |
ISO |
Alitretinoin results in decreased expression of HGF mRNA Alitretinoin results in decreased secretion of HGF protein Alitretinoin results in increased expression of HGF mRNA Alitretinoin results in increased secretion of HGF protein |
CTD |
PMID:11223164 PMID:16192631 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [Dimethylformamide results in decreased expression of HMOX1 protein] |
CTD |
PMID:31875996 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression |
EXP |
Alitretinoin results in decreased expression of HNF4A mRNA |
CTD |
PMID:21115832 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of HNRNPA2B1 protein |
CTD |
PMID:28886987 |
|
NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
increases expression |
EXP |
Alitretinoin results in increased expression of HPGDS mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
|
|
G |
Hps5 |
HPS5, biogenesis of lysosomal organelles complex 2 subunit 2 |
increases expression |
EXP |
Alitretinoin results in increased expression of SAA2 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 1:97,281,626...97,320,945
Ensembl chr 1:97,247,598...97,321,019
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of HSD11B1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
increases activity increases expression |
ISO |
Alitretinoin results in increased activity of HSD17B1 protein Alitretinoin results in increased expression of HSD17B1 mRNA |
CTD |
PMID:16513093 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of HSPH1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases secretion decreases expression |
ISO |
[22-hydroxycholesterol co-treated with Alitretinoin] inhibits the reaction [IFNG promotes the reaction [STAT1 protein binds to CCL2 promoter]]; [22-hydroxycholesterol co-treated with Alitretinoin] inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Alitretinoin inhibits the reaction [IFNG results in increased expression of NR1H3 mRNA]; Alitretinoin inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein] Alitretinoin results in decreased secretion of IFNG protein Alitretinoin results in decreased expression of IFNG mRNA; Alitretinoin results in decreased expression of IFNG protein |
CTD |
PMID:11970994 PMID:17118196 PMID:21268089 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of IFNGR1 protein |
CTD |
PMID:16085646 |
|
NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression increases expression |
ISO |
Alitretinoin results in decreased expression of IGF1 protein Alitretinoin results in increased expression of IGF1 mRNA |
CTD |
PMID:15982314 PMID:15994153 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
EXP |
Alitretinoin results in increased expression of IGFBP2 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
affects binding increases expression |
ISO |
[Alitretinoin binds to RARB protein] which binds to IGFBP3 promoter Alitretinoin results in increased expression of IGFBP3 mRNA; Alitretinoin results in increased expression of IGFBP3 protein |
CTD |
PMID:15994153 PMID:16760641 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Il10ra |
interleukin 10 receptor subunit alpha |
decreases expression |
ISO |
Alitretinoin results in decreased expression of IL10RA mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; Alitretinoin results in decreased expression of [IL12A protein binds to IL12B protein] |
CTD |
PMID:17118196 PMID:17475839 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; Alitretinoin results in decreased expression of [IL12A protein binds to IL12B protein] Alitretinoin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:16303184 PMID:17118196 PMID:17475839 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
Alitretinoin results in increased expression of IL13 mRNA; Alitretinoin results in increased expression of IL13 protein |
CTD |
PMID:17118196 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
[Fenofibrate co-treated with Alitretinoin] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Alitretinoin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] Alitretinoin results in increased expression of IL1B mRNA |
CTD |
PMID:15968640 PMID:15982314 PMID:16303184 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions decreases expression |
ISO |
Alitretinoin promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2 protein] Alitretinoin results in decreased expression of IL2 mRNA; Alitretinoin results in decreased expression of IL2 protein |
CTD |
PMID:12421932 PMID:17118196 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il24 |
interleukin 24 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of IL24 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions increases secretion |
ISO |
Alitretinoin results in increased expression of IL4 mRNA; Alitretinoin results in increased expression of IL4 protein IL4 protein promotes the reaction [Alitretinoin results in increased secretion of IL4 protein] |
CTD |
PMID:11970994 PMID:17118196 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
Alitretinoin results in increased expression of IL5 mRNA; Alitretinoin results in increased expression of IL5 protein |
CTD |
PMID:17118196 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Fenofibrate co-treated with Alitretinoin] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:15968640 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in decreased expression of CDKN1B protein]; Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in increased expression of CCNA2 protein]; Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in increased phosphorylation of RB1 protein] [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with Alitretinoin] results in increased expression of SLC27A1 mRNA; [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with Alitretinoin] results in increased uptake of Oleic Acid; [Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased susceptibility to Alitretinoin; Dactinomycin inhibits the reaction [[[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with Alitretinoin] results in increased expression of SLC27A1 mRNA] |
CTD |
PMID:10777552 PMID:11348869 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
increases phosphorylation |
EXP |
Alitretinoin results in increased phosphorylation of INSR protein |
CTD |
PMID:18063688 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irf1 |
interferon regulatory factor 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of IRF1; Alitretinoin results in increased expression of IRF1 mRNA; Alitretinoin results in increased expression of IRF1 protein |
CTD |
PMID:16085646 PMID:16636311 PMID:17229644 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Itga4 |
integrin subunit alpha 4 |
increases expression |
ISO |
Alitretinoin results in increased expression of ITGA4 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of ITGAM protein]; Vitamin D promotes the reaction [Alitretinoin results in increased expression of ITGAM protein] |
CTD |
PMID:15964820 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgax |
integrin subunit alpha X |
multiple interactions |
ISO |
Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of ITGAX protein]; Vitamin D promotes the reaction [Alitretinoin results in increased expression of ITGAX protein] |
CTD |
PMID:15964820 |
|
NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of ITGB2 protein] |
CTD |
PMID:15964820 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Ivl |
involucrin |
increases expression decreases expression |
ISO |
Alitretinoin results in increased expression of IVL mRNA Alitretinoin results in decreased expression of IVL mRNA |
CTD |
PMID:8853895 PMID:17034753 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Alitretinoin co-treated with Tretinoin co-treated with Calcitriol] results in increased expression of JUN protein; Alitretinoin inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein] |
CTD |
PMID:8950452 PMID:19812349 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klk10 |
kallikrein related-peptidase 10 |
increases expression |
ISO |
Alitretinoin results in increased expression of KLK10 mRNA; Alitretinoin results in increased expression of KLK10 protein |
CTD |
PMID:16800735 |
|
NCBI chr 1:94,234,536...94,239,369
Ensembl chr 1:94,235,096...94,239,376
|
|
G |
Krt1 |
keratin 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of KRT1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of KRT10 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Krt14 |
keratin 14 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of KRT14 mRNA |
CTD |
PMID:8853895 PMID:15982314 |
|
NCBI chr10:85,137,786...85,142,054
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt15 |
keratin 15 |
increases expression |
ISO |
Alitretinoin results in increased expression of KRT15 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt17 |
keratin 17 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of KRT17 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Alitretinoin results in increased expression of KRT18 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Alitretinoin results in increased expression of KRT19 mRNA; Alitretinoin results in increased expression of KRT19 protein |
CTD |
PMID:11214822 PMID:15982314 PMID:17034753 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt5 |
keratin 5 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of KRT5 mRNA |
CTD |
PMID:8853895 PMID:15982314 |
|
NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Krt7 |
keratin 7 |
increases expression |
ISO |
Alitretinoin results in increased expression of KRT7 mRNA; Alitretinoin results in increased expression of KRT7 protein |
CTD |
PMID:15982314 PMID:17034753 |
|
NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052
|
|
G |
Krt75 |
keratin 75 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of KRT75 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 7:132,687,101...132,697,360
Ensembl chr 7:132,688,237...132,697,345
|
|
G |
Krt8 |
keratin 8 |
increases expression |
ISO |
Alitretinoin results in increased expression of KRT8 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lama2 |
laminin subunit alpha 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of LAMA2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530
|
|
G |
Lama3 |
laminin subunit alpha 3 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of LAMA3 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamc3 |
laminin subunit gamma 3 |
increases expression |
ISO |
Alitretinoin results in increased expression of LAMC3 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 3:15,165,220...15,226,697
Ensembl chr 3:15,165,220...15,226,697
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Alitretinoin results in increased expression of LCN2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
[Alitretinoin co-treated with Clofibrate] results in increased expression of LEP protein |
CTD |
PMID:9751766 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions increases expression |
ISO |
[Alitretinoin co-treated with 22-hydroxycholesterol] results in increased expression of LPL mRNA; [Alitretinoin co-treated with T0901317] results in increased expression of LPL mRNA Alitretinoin results in increased expression of LPL mRNA |
CTD |
PMID:16142410 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lypla1 |
lysophospholipase 1 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of LYPLA1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 5:14,679,605...14,708,774
Ensembl chr 5:14,679,606...14,708,746
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression decreases expression |
ISO |
Alitretinoin results in increased expression of MAP2 protein Alitretinoin results in decreased expression of MAP2 mRNA; Alitretinoin results in decreased expression of MAP2 protein |
CTD |
PMID:23500671 PMID:36805303 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
Alitretinoin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:16043492 PMID:16611854 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of MAPK3 protein Alitretinoin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein |
CTD |
PMID:16043492 PMID:16611854 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mark1 |
microtubule affinity regulating kinase 1 |
increases expression |
EXP |
Alitretinoin results in increased expression of MARK1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr13:96,450,189...96,555,304
Ensembl chr13:96,451,487...96,555,173
|
|
G |
Meis1 |
Meis homeobox 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of MEIS1 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr14:93,155,426...93,294,373
Ensembl chr14:93,155,419...93,294,265
|
|
G |
Meis2 |
Meis homeobox 2 |
increases expression |
ISO |
Alitretinoin results in increased expression of MEIS2 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr 3:102,742,904...102,944,833
Ensembl chr 3:102,742,900...102,949,696
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of MEOX1 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases phosphorylation |
ISO |
Alitretinoin results in increased phosphorylation of MET protein |
CTD |
PMID:16192631 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mfap2 |
microfibril associated protein 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of MFAP2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259
|
|
G |
Mir148b |
microRNA 148b |
multiple interactions |
ISO |
[Arsenicals co-treated with Alitretinoin] results in decreased expression of MIR148B mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494
|
|
G |
Mir152 |
microRNA 152 |
multiple interactions |
ISO |
[Arsenicals co-treated with Alitretinoin] results in decreased expression of MIR152 mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of MIR152 mRNA |
CTD |
PMID:34303791 |
|
NCBI chr10:81,832,936...81,833,020
Ensembl chr10:81,832,936...81,833,020
|
|
G |
Mitf |
melanocyte inducing transcription factor |
increases expression |
ISO |
Alitretinoin results in increased expression of MITF mRNA |
CTD |
PMID:23489423 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of MMP10 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
Alitretinoin results in increased expression of MTTP mRNA |
CTD |
PMID:15537571 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
increases expression |
ISO |
Alitretinoin results in increased expression of MUC5AC mRNA |
CTD |
PMID:17034753 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Alitretinoin] promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to NCOA1 protein]; [Alitretinoin co-treated with NCOA1 protein] results in increased activity of RXRB protein; Alitretinoin promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to NCOA1 protein] |
CTD |
PMID:17223708 PMID:22227104 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ndufaf3 |
NADH:ubiquinone oxidoreductase complex assembly factor 3 |
increases expression |
EXP |
Alitretinoin results in increased expression of NDUFAF3 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 8:109,261,362...109,263,194
Ensembl chr 8:109,261,363...109,263,194
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
increases expression |
ISO |
Alitretinoin results in increased expression of NEDD9 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019
|
|
G |
Nefh |
neurofilament heavy chain |
increases expression |
ISO |
Alitretinoin results in increased expression of NEFH protein |
CTD |
PMID:23500671 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
decreases expression affects expression |
ISO |
Alitretinoin results in decreased expression of NEFL mRNA Alitretinoin affects the expression of NEFL protein |
CTD |
PMID:15982314 PMID:36805303 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
increases expression |
ISO |
Alitretinoin results in increased expression of NEFM protein |
CTD |
PMID:8892963 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nes |
nestin |
decreases expression |
ISO |
Alitretinoin results in decreased expression of NES mRNA; Alitretinoin results in decreased expression of NES protein |
CTD |
PMID:36805303 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP ISO |
[9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] results in increased activity of NFE2L2 protein Alitretinoin inhibits the reaction [Dimethylformamide results in decreased activity of NFE2L2 protein] |
CTD |
PMID:15150131 PMID:31875996 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of NKX3-1 mRNA; Alitretinoin results in increased expression of NKX3-1 protein |
CTD |
PMID:16763719 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of NME2 protein |
CTD |
PMID:28886987 |
|
NCBI chr10:78,898,097...78,903,514
Ensembl chr10:78,897,770...78,903,538
|
|
G |
Npm1 |
nucleophosmin 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of NPM1 protein |
CTD |
PMID:28886987 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [Dimethylformamide results in decreased expression of NQO1 protein] |
CTD |
PMID:31875996 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
[Alitretinoin co-treated with 22-hydroxycholesterol] affects the localization of NR1H2 protein |
CTD |
PMID:16888799 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[Alitretinoin co-treated with 22-hydroxycholesterol] affects the localization of NR1H3 protein; Alitretinoin inhibits the reaction [IFNG results in increased expression of NR1H3 mRNA] |
CTD |
PMID:16888799 PMID:21268089 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Alitretinoin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:16632523 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [Alitretinoin promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter]]; [1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Alitretinoin] promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to NCOA1 protein]; Alitretinoin binds to and results in increased activity of NR1I3 protein alternative form; Alitretinoin promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter]]; Alitretinoin promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to NCOA1 protein]; Alitretinoin promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter] Alitretinoin results in increased activity of [RXRA protein binds to NR1I3 protein] |
CTD |
PMID:17223708 PMID:19686701 PMID:31312845 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions decreases expression |
ISO |
Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Alitretinoin inhibits the reaction [NR5A2 protein results in increased expression of CYP19A1 mRNA] Alitretinoin results in decreased expression of NR5A2 mRNA |
CTD |
PMID:16357189 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Nrl |
neural retina leucine zipper |
increases expression |
ISO |
Alitretinoin results in increased expression of NRL mRNA; Alitretinoin results in increased expression of NRL protein |
CTD |
PMID:16854989 |
|
NCBI chr15:29,007,059...29,011,480
Ensembl chr15:29,008,104...29,009,832
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of ODC1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of OLR1 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
P2rx2 |
purinergic receptor P2X 2 |
increases expression |
EXP |
Alitretinoin results in increased expression of P2RX2 mRNA; Alitretinoin results in increased expression of P2RX2 protein |
CTD |
PMID:16638968 |
|
NCBI chr12:46,338,979...46,342,891
Ensembl chr12:46,339,549...46,342,891
|
|
G |
Padi4 |
peptidyl arginine deiminase 4 |
multiple interactions increases expression |
ISO |
Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of PADI4 mRNA] |
CTD |
PMID:15964820 |
|
NCBI chr 5:153,041,351...153,074,412
Ensembl chr 5:153,041,352...153,074,362
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Alitretinoin results in increased cleavage of PARP1 protein |
CTD |
PMID:16449964 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax6 |
paired box 6 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of PAX6 mRNA; Alitretinoin results in decreased expression of PAX6 protein |
CTD |
PMID:36805303 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP ISO |
Alitretinoin results in increased expression of PCK1 mRNA [Tretinoin co-treated with Alitretinoin] affects the reaction [Vitamin A affects the expression of PCK1 mRNA] |
CTD |
PMID:16317119 PMID:17320364 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Alitretinoin results in increased expression of PCSK2 mRNA |
CTD |
PMID:15585599 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in decreased expression of CDKN1B protein]; Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in increased expression of CCNA2 protein]; Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in increased phosphorylation of RB1 protein] |
CTD |
PMID:11348869 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
decreases expression |
ISO EXP |
Alitretinoin results in decreased expression of PDX1 mRNA |
CTD |
PMID:21115832 PMID:21670153 |
|
NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
|
|
G |
Per1 |
period circadian regulator 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of PER1 mRNA |
CTD |
PMID:17069763 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Pex19 |
peroxisomal biogenesis factor 19 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of PEX19 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr13:84,592,277...84,608,793
Ensembl chr13:84,592,312...84,608,608
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of PIK3R1 mRNA; Alitretinoin results in increased expression of PIK3R1 protein |
CTD |
PMID:16288212 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
increases expression |
EXP |
Alitretinoin results in increased expression of PIK3R3 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583
|
|
G |
Pir |
pirin |
increases expression |
ISO |
Alitretinoin results in increased expression of PIR mRNA |
CTD |
PMID:15982314 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Pkm |
pyruvate kinase M1/2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of PKM protein |
CTD |
PMID:28886987 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
Alitretinoin results in increased expression of PLAT mRNA |
CTD |
PMID:15982314 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[pirinixic acid co-treated with Alitretinoin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA |
CTD |
PMID:16292757 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity multiple interactions |
ISO EXP |
Alitretinoin results in increased activity of PPARG protein [9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] promotes the reaction [[PPARG protein binds to RXRA protein] which binds to GSTA2 promoter]; Alitretinoin binds to and results in increased activity of PPARG protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Alitretinoin results in increased activity of PPARG protein]; MG 262 promotes the reaction [Alitretinoin results in increased activity of PPARG protein] [Pioglitazone co-treated with Alitretinoin] inhibits the reaction [PPARG protein results in increased susceptibility to Methamphetamine]; PPARG protein promotes the reaction [Alitretinoin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:15150131 PMID:15707588 PMID:16513826 PMID:17019405 PMID:18063688 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Alitretinoin results in increased expression of PPARGC1A mRNA 2-chloro-5-nitrobenzanilide inhibits the reaction [Alitretinoin results in increased expression of PPARGC1A mRNA]; PPARG protein promotes the reaction [Alitretinoin results in increased expression of PPARGC1A mRNA]; RXRA protein promotes the reaction [Alitretinoin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:16513826 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Pramex1 |
PRAME like, X-linked 1 |
multiple interactions |
ISO |
Alitretinoin promotes the reaction [RARA protein binds to PRAME protein] |
CTD |
PMID:16179254 |
|
NCBI chr X:98,567,994...98,574,654
Ensembl chr X:98,569,415...98,572,096
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in increased expression of PTEN protein |
CTD |
PMID:16611854 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of PTGS1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of PTGS2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression multiple interactions |
ISO |
Alitretinoin results in decreased expression of PTHLH mRNA Alitretinoin promotes the reaction [Calcitriol results in decreased expression of PTHLH mRNA] |
CTD |
PMID:16243370 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Rab11b |
RAB11B, member RAS oncogene family |
increases expression |
EXP |
Alitretinoin results in increased expression of RAB11B mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 7:14,521,448...14,534,589
Ensembl chr 7:14,521,368...14,534,593
|
|
G |
Rab27a |
RAB27A, member RAS oncogene family |
decreases response to substance decreases expression |
ISO |
RAB27A gene mutant form results in decreased susceptibility to Alitretinoin Alitretinoin results in decreased expression of RAB27A mRNA |
CTD |
PMID:16449964 |
|
NCBI chr 8:73,782,730...73,836,630
Ensembl chr 8:73,782,694...73,847,829
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression multiple interactions decreases expression |
EXP ISO |
Alitretinoin results in increased expression of RARA protein [Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [Alitretinoin results in increased activity of RARA protein]; CAMK4 protein promotes the reaction [Alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [Alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [Alitretinoin results in increased activity of RARA protein]]; Okadaic Acid promotes the reaction [Alitretinoin results in increased activity of RARA protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [Alitretinoin results in increased activity of RARA protein]]; trichostatin A promotes the reaction [Alitretinoin results in increased activity of RARA protein] Alitretinoin results in decreased expression of RARA protein Alitretinoin results in increased expression of RARA mRNA Alitretinoin binds to and results in increased activity of RARA protein; Alitretinoin promotes the reaction [RARA protein binds to PRAME protein]; RARA protein promotes the reaction [Alitretinoin results in increased expression of ABCC6 mRNA] |
CTD |
PMID:8892963 PMID:11139446 PMID:15375546 PMID:15773917 PMID:16043492 PMID:16179254 PMID:17034753 PMID:17045963 PMID:18180267 PMID:36805303 More...
|
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rarb |
retinoic acid receptor, beta |
affects binding multiple interactions increases expression |
ISO |
[Alitretinoin binds to RARB protein] which binds to IGFBP3 promoter Alitretinoin binds to [RXRA protein binds to RARB protein] [Alitretinoin co-treated with RXRA protein] results in increased expression of RARB mRNA; sodium arsenite inhibits the reaction [[Alitretinoin co-treated with RXRA protein] results in increased expression of RARB mRNA] [Arsenicals co-treated with Alitretinoin] affects the expression of RARB mRNA; [Arsenicals co-treated with Alitretinoin] results in decreased expression of RARB protein; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB protein; Alitretinoin binds to and results in increased activity of RARB protein Alitretinoin results in increased expression of RARB mRNA Alitretinoin results in increased expression of RARB mRNA; Alitretinoin results in increased expression of RARB protein |
CTD |
PMID:8892963 PMID:11139446 PMID:15159591 PMID:15375546 PMID:16413115 PMID:16760641 PMID:18180267 PMID:22310326 PMID:34303791 PMID:36805303 More...
|
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rarg |
retinoic acid receptor, gamma |
decreases expression increases expression increases activity multiple interactions decreases response to substance |
ISO |
Alitretinoin results in decreased expression of RARG protein Alitretinoin results in increased expression of RARG mRNA Alitretinoin results in increased activity of RARG protein Alitretinoin binds to and results in increased activity of RARG protein RARG gene mutant form results in decreased susceptibility to Alitretinoin |
CTD |
PMID:10748128 PMID:15375546 PMID:15615532 PMID:18180267 PMID:19812349 PMID:30639747 PMID:36805303 More...
|
|
NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Rarres1 |
retinoic acid receptor responder 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of RARRES1 mRNA |
CTD |
PMID:17034753 |
|
NCBI chr 2:151,749,715...151,783,975
Ensembl chr 2:151,749,715...151,783,978
|
|
G |
Rasl11a |
RAS-like family 11 member A |
increases expression |
EXP |
Alitretinoin results in increased expression of RASL11A mRNA |
CTD |
PMID:16648578 |
|
NCBI chr12:8,258,148...8,260,909
Ensembl chr12:8,258,159...8,262,576
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions decreases phosphorylation |
ISO |
Alitretinoin inhibits the reaction [[[PDGFB protein binds to PDGFB protein] which co-treated with INS protein] results in increased phosphorylation of RB1 protein] Alitretinoin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:11348869 PMID:16273314 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbfox3 |
RNA binding fox-1 homolog 3 |
increases expression |
ISO |
Alitretinoin results in increased expression of RBFOX3 mRNA |
CTD |
PMID:36805303 |
|
NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935
|
|
G |
Rbp1 |
retinol binding protein 1 |
increases abundance |
ISO |
RBP1 gene mutant form results in increased abundance of Alitretinoin |
CTD |
PMID:21670153 |
|
NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743
|
|
G |
Rbp2 |
retinol binding protein 2 |
increases expression |
EXP |
Alitretinoin results in increased expression of RBP2 mRNA |
CTD |
PMID:19409899 |
|
NCBI chr 8:99,079,293...99,104,489
Ensembl chr 8:99,079,104...99,104,473
|
|
G |
Rest |
RE1-silencing transcription factor |
increases expression |
EXP |
Alitretinoin results in increased expression of REST mRNA |
CTD |
PMID:16648578 |
|
NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354
|
|
G |
Retn |
resistin |
decreases expression decreases secretion |
ISO |
Alitretinoin results in decreased expression of RETN mRNA Alitretinoin results in decreased secretion of RETN protein |
CTD |
PMID:15047602 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
ISO |
Alitretinoin results in decreased expression of RHOA mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
decreases expression |
ISO |
Alitretinoin results in decreased expression of RHOB mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rnf5 |
ring finger protein 5 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of RNF5 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr20:4,145,539...4,147,985
Ensembl chr20:4,145,507...4,147,985
|
|
G |
Rpl22 |
ribosomal protein L22 |
increases expression |
EXP |
Alitretinoin results in increased expression of RPL22 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 5:162,835,241...162,843,394
Ensembl chr 5:162,833,740...162,843,368 Ensembl chr 7:162,833,740...162,843,368 Ensembl chr 4:162,833,740...162,843,368
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of RPS6KA1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions increases activity affects binding increases ubiquitination increases expression increases degradation decreases expression affects localization increases localization |
ISO EXP |
[Alitretinoin co-treated with RXRA protein] results in increased expression of RARB mRNA; Alitretinoin binds to and results in increased activity of RXRA protein; Alitretinoin inhibits the reaction [TGIF1 protein binds to RXRA protein]; Alitretinoin inhibits the reaction [TGIF1 protein results in increased activity of RXRA protein]; Alitretinoin results in increased activity of [RXRA protein binds to NR1I3 protein]; Alitretinoin results in increased activity of [RXRA protein binds to RXRA protein]; ethyl(E,E,E)-7-(2-n-propoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-3-yl)-6-fluorp-3-methylocta-2,4,6-trienoate inhibits the reaction [Alitretinoin results in increased activity of [RXRA protein binds to RXRA protein]]; RXRA protein promotes the reaction [Alitretinoin results in increased expression of PPARGC1A mRNA]; sodium arsenite inhibits the reaction [[Alitretinoin co-treated with RXRA protein] results in increased expression of RARB mRNA] Alitretinoin results in increased activity of RXRA protein Alitretinoin binds to RXRA protein Alitretinoin results in increased ubiquitination of RXRA protein Alitretinoin binds to [RXRA protein binds to RARB protein] Alitretinoin results in increased expression of RXRA protein Alitretinoin binds to RXRA protein; RXRA protein binds to Alitretinoin Alitretinoin results in increased degradation of RXRA protein [9-deoxy-delta-9-prostaglandin D2 co-treated with Alitretinoin] promotes the reaction [[PPARG protein binds to RXRA protein] which binds to GSTA2 promoter] Alitretinoin results in decreased expression of RXRA protein 1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [Alitretinoin promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter]]; [1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Alitretinoin] promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to NCOA1 protein]; [Alitretinoin binds to and results in increased activity of RXRA protein] which results in increased expression of CYP19A1 protein; [Alitretinoin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the localization of RXRA protein; [Alitretinoin co-treated with Calcitriol] results in increased stability of [RXRA protein binds to VDR protein]; [Alitretinoin co-treated with RXRA protein] results in increased expression of PSG5 mRNA; [Alitretinoin results in increased activity of RXRA protein] which binds to PSG5 promoter; [pirinixic acid co-treated with Alitretinoin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; Alitretinoin analog binds to and results in increased activity of RXRA protein; Alitretinoin binds to and affects the activity of RXRA protein; Alitretinoin binds to and results in increased activity of RXRA protein; Alitretinoin inhibits the reaction [Dimethylformamide results in decreased degradation of RXRA protein]; Alitretinoin inhibits the reaction [triphenyltin hydroxide binds to RXRA protein]; Alitretinoin promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter]]; Alitretinoin promotes the reaction [[NR1I3 protein binds to RXRA protein] which binds to NCOA1 protein]; Alitretinoin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Alitretinoin promotes the reaction [[RXRA protein binds to NR1I3 protein] which binds to CYP3A4 promoter]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Alitretinoin results in increased degradation of RXRA protein]; Flurbiprofen inhibits the reaction [Alitretinoin binds to RXRA protein]; RXRA promotes the reaction [Alitretinoin results in increased expression of APOA2 mRNA]; RXRA protein affects the reaction [Alitretinoin results in increased expression of CYP2B6 mRNA]; tributyltin inhibits the reaction [Alitretinoin binds to RXRA protein]; triphenyl bismuth inhibits the reaction [Alitretinoin binds to RXRA protein]; triphenylarsine inhibits the reaction [Alitretinoin binds to RXRA protein]; triphenyltin chloride inhibits the reaction [Alitretinoin binds to RXRA protein]; triphenyltin hydroxide inhibits the reaction [Alitretinoin binds to RXRA protein] Alitretinoin affects the localization of RXRA protein Alitretinoin results in increased expression of RXRA mRNA Alitretinoin results in increased localization of RXRA protein |
CTD |
PMID:8668150 PMID:11139446 PMID:15150131 PMID:15159591 PMID:15375546 PMID:15866424 PMID:15941851 PMID:15997096 PMID:16043492 PMID:16184197 PMID:16204233 PMID:16258897 PMID:16292757 PMID:16428452 PMID:16460010 PMID:16513826 PMID:16632523 PMID:16946489 PMID:17084873 PMID:17170071 PMID:17223708 PMID:17475324 PMID:19659691 PMID:19686701 PMID:19812349 PMID:22310326 PMID:27725436 PMID:30639747 PMID:31195007 PMID:31312845 PMID:31566444 PMID:31875996 More...
|
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Rxrb |
retinoid X receptor beta |
increases degradation affects binding increases activity increases expression multiple interactions |
ISO EXP |
Alitretinoin results in increased degradation of RXRB protein Alitretinoin binds to RXRB protein Alitretinoin results in increased activity of RXRB protein Alitretinoin results in increased expression of RXRB protein 2,4,6-trichlorophenol inhibits the reaction [Alitretinoin binds to and results in increased activity of RXRB protein]; [Alitretinoin co-treated with NCOA1 protein] results in increased activity of RXRB protein; Alitretinoin binds to and affects the activity of RXRB protein; Alitretinoin promotes the reaction [RXRB protein binds to BGLAP gene]; bisphenol A analog inhibits the reaction [Alitretinoin binds to and results in increased activity of RXRB protein]; bisphenol A inhibits the reaction [Alitretinoin binds to and results in increased activity of RXRB protein]; tetrachlorodian inhibits the reaction [Alitretinoin binds to and results in increased activity of RXRB protein] |
CTD |
PMID:11939783 PMID:12898515 PMID:15941851 PMID:16043492 PMID:18207673 PMID:22227104 PMID:27565853 PMID:31195007 More...
|
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
increases expression multiple interactions decreases expression affects activity affects binding |
ISO |
Alitretinoin results in increased expression of RXRG mRNA Alitretinoin binds to and affects the activity of RXRG protein Alitretinoin results in decreased expression of RXRG mRNA Alitretinoin affects the activity of RXRG protein Alitretinoin binds to RXRG protein |
CTD |
PMID:8892963 PMID:9092800 PMID:11139446 PMID:12114515 PMID:15941851 PMID:31195007 More...
|
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
S100a1 |
S100 calcium binding protein A1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of S100A1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:175,993,922...175,998,765
Ensembl chr 2:175,993,922...175,999,544
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of S100A8 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Alitretinoin results in increased expression of S100A9 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
S100b |
S100 calcium binding protein B |
increases expression |
ISO |
Alitretinoin results in increased expression of S100B mRNA |
CTD |
PMID:36805303 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of SCARB1 mRNA |
CTD |
PMID:16142410 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Alitretinoin results in increased expression of SCD mRNA |
CTD |
PMID:11397803 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sema6b |
semaphorin 6B |
multiple interactions |
ISO |
Alitretinoin promotes the reaction [Fenofibrate results in decreased expression of SEMA6B mRNA]; Alitretinoin promotes the reaction [Fenofibrate results in decreased expression of SEMA6B protein]; Alitretinoin promotes the reaction [Troglitazone results in decreased expression of SEMA6B mRNA]; Alitretinoin promotes the reaction [Troglitazone results in decreased expression of SEMA6B protein] |
CTD |
PMID:16525649 |
|
NCBI chr 9:950,939...967,905
Ensembl chr 9:950,939...961,521
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
increases expression |
ISO |
Alitretinoin results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Serpinb2 |
serpin family B member 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SERPINB2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpinb8 |
serpin family B member 8 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SERPINB8 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr13:23,626,936...23,650,277
Ensembl chr13:23,626,945...23,650,835
|
|
G |
Serpinb9 |
serpin family B member 9 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SERPINB9 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] |
CTD |
PMID:16192631 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SLC16A1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
multiple interactions increases expression |
ISO EXP |
[[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with Alitretinoin] results in increased expression of SLC27A1 mRNA; Dactinomycin inhibits the reaction [[[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with Alitretinoin] results in increased expression of SLC27A1 mRNA] Alitretinoin results in increased expression of SLC27A1 mRNA Dactinomycin inhibits the reaction [Alitretinoin results in increased expression of SLC27A1 mRNA] |
CTD |
PMID:10777552 |
|
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases activity decreases expression |
EXP ISO |
Alitretinoin results in decreased activity of SLC2A2 protein Alitretinoin results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:21115832 PMID:21670153 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
EXP |
Alitretinoin results in increased expression of SLC2A4 mRNA; Alitretinoin results in increased expression of SLC2A4 protein |
CTD |
PMID:16273324 PMID:18063688 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
increases expression |
ISO |
Alitretinoin results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16954431 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
[T0901317 co-treated with Alitretinoin] results in increased expression of SMAD3 protein |
CTD |
PMID:17194744 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snn |
stannin |
decreases expression |
EXP |
Alitretinoin results in decreased expression of SNN mRNA |
CTD |
PMID:16648578 |
|
NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SOCS1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
increases expression |
ISO |
Alitretinoin results in increased expression of SOCS2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Sox1 |
SRY-box transcription factor 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SOX1 mRNA |
CTD |
PMID:36805303 |
|
NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SOX2 mRNA |
CTD |
PMID:36805303 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
increases expression |
EXP |
Alitretinoin results in increased expression of SPINK1 mRNA |
CTD |
PMID:16648578 |
|
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression increases expression |
ISO |
Alitretinoin results in decreased expression of SPP1 mRNA Alitretinoin results in increased expression of SPP1 mRNA Alitretinoin results in decreased expression of SPP1 mRNA; Alitretinoin results in decreased expression of SPP1 protein |
CTD |
PMID:11139446 PMID:16392701 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sprr1b |
small proline-rich protein 1B |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SPRR1B mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[22-hydroxycholesterol co-treated with Alitretinoin] inhibits the reaction [Arsenic Trioxide results in decreased expression of SREBF1 protein] |
CTD |
PMID:27622732 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[22-hydroxycholesterol co-treated with Alitretinoin] inhibits the reaction [IFNG promotes the reaction [STAT1 protein binds to CCL2 promoter]]; [22-hydroxycholesterol co-treated with Alitretinoin] inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Alitretinoin inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Alitretinoin results in increased phosphorylation of and results in increased activity of STAT1 protein |
CTD |
PMID:16085646 PMID:21268089 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Sts |
steroid sulfatase |
increases activity |
ISO |
Alitretinoin results in increased activity of STS protein |
CTD |
PMID:16178010 |
|
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Syp |
synaptophysin |
decreases expression |
ISO |
Alitretinoin results in decreased expression of SYP mRNA |
CTD |
PMID:36805303 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tacstd2 |
tumor-associated calcium signal transducer 2 |
increases expression |
ISO |
Alitretinoin results in increased expression of TACSTD2 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 4:96,707,950...96,709,650
Ensembl chr 4:96,707,951...96,709,650
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
increases phosphorylation multiple interactions |
EXP |
Alitretinoin results in increased phosphorylation of TBC1D4 protein Oligomycins promotes the reaction [Alitretinoin results in increased phosphorylation of TBC1D4 protein] |
CTD |
PMID:18063688 |
|
NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases expression |
ISO |
Alitretinoin results in decreased expression of TERT mRNA |
CTD |
PMID:16180984 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases response to substance decreases activity decreases expression |
ISO |
Alitretinoin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] Alitretinoin results in decreased susceptibility to TGFB1 protein 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [Alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[Alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Alitretinoin] results in decreased expression of TGFB1 mRNA] Alitretinoin results in decreased activity of TGFB1 protein |
CTD |
PMID:16192631 PMID:16611854 PMID:21152098 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb1i1 |
transforming growth factor beta 1 induced transcript 1 |
increases expression |
ISO |
Alitretinoin results in increased expression of TGFB1I1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:182,828,544...182,837,080
|
|
G |
Tgif1 |
TGFB-induced factor homeobox 1 |
increases expression multiple interactions |
ISO |
Alitretinoin results in increased expression of TGIF1 protein Alitretinoin inhibits the reaction [TGIF1 protein binds to RXRA protein]; Alitretinoin inhibits the reaction [TGIF1 protein results in increased activity of RXRA protein] |
CTD |
PMID:16192631 PMID:16428452 |
|
NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802
|
|
G |
Tgm1 |
transglutaminase 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of TGM1 mRNA |
CTD |
PMID:8853895 PMID:15982314 |
|
NCBI chr15:29,191,039...29,206,000
Ensembl chr15:29,191,041...29,204,523
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions increases expression increases activity |
ISO |
[Alitretinoin co-treated with Dimethyl Sulfoxide] promotes the reaction [H3-4 protein modified form binds to TGM2 gene]; [Alitretinoin co-treated with Dimethyl Sulfoxide] promotes the reaction [H4C16 protein modified form binds to TGM2 gene]; Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of TGM2 mRNA]; Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of TGM2 protein]; periodate-oxidized adenosine inhibits the reaction [Alitretinoin results in increased expression of TGM2 mRNA]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Alitretinoin results in increased expression of TGM2 mRNA]]; Vitamin D promotes the reaction [Alitretinoin results in increased expression of TGM2 mRNA] Alitretinoin results in increased expression of TGM2 mRNA; Alitretinoin results in increased expression of TGM2 protein Alitretinoin results in increased activity of TGM2 protein |
CTD |
PMID:9516142 PMID:15964820 PMID:16158052 PMID:17034753 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Th |
tyrosine hydroxylase |
decreases expression |
ISO |
Alitretinoin results in decreased expression of TH protein |
CTD |
PMID:36805303 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
ISO |
Alitretinoin results in decreased expression of THBS1 mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO |
[Fenofibrate co-treated with Alitretinoin] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Alitretinoin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Alitretinoin results in decreased expression of TNF mRNA; Alitretinoin results in decreased expression of TNF protein Alitretinoin inhibits the reaction [TNF protein results in increased expression of CYP4F11 mRNA]; Alitretinoin inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein] |
CTD |
PMID:15968640 PMID:16303184 PMID:17118196 PMID:19812349 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
Alitretinoin results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:16449964 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
ISO |
Alitretinoin results in increased expression of TNFSF10 mRNA; Alitretinoin results in increased expression of TNFSF10 protein |
CTD |
PMID:16449964 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
decreases expression |
ISO |
Alitretinoin results in decreased expression of TSHB mRNA; Alitretinoin results in decreased expression of TSHB protein |
CTD |
PMID:9092800 PMID:16306084 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ttr |
transthyretin |
decreases expression |
EXP |
Alitretinoin results in decreased expression of TTR mRNA |
CTD |
PMID:16648578 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
EXP |
Alitretinoin results in increased expression of TUBA1A mRNA |
CTD |
PMID:16648578 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
decreases expression |
ISO |
Alitretinoin results in decreased expression of TUBB3 mRNA |
CTD |
PMID:36805303 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
Alitretinoin results in increased expression of TYR mRNA; Alitretinoin results in increased expression of TYR protein |
CTD |
PMID:23489423 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression multiple interactions |
EXP ISO |
Alitretinoin results in increased expression of UCP1 mRNA 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Alitretinoin results in increased expression of UCP1 mRNA]; Glutathione inhibits the reaction [Alitretinoin results in increased expression of UCP1 mRNA] |
CTD |
PMID:10600643 PMID:12414803 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
multiple interactions |
ISO |
[pirinixic acid co-treated with Alitretinoin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA |
CTD |
PMID:16292757 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
EXP |
Alitretinoin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:14620509 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases expression |
EXP |
Alitretinoin results in increased expression of UGT1A2 mRNA |
CTD |
PMID:14620509 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a3 |
UDP glycosyltransferase 1 family, polypeptide A3 |
increases expression |
EXP |
Alitretinoin results in increased expression of UGT1A5 mRNA |
CTD |
PMID:14620509 |
|
NCBI chr 9:88,780,328...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases expression |
EXP |
Alitretinoin results in decreased expression of UGT1A6 mRNA |
CTD |
PMID:14620509 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b |
UDP glycosyltransferase 2 family, polypeptide B |
decreases expression |
EXP |
Alitretinoin results in decreased expression of UGT2B mRNA |
CTD |
PMID:16648578 |
|
NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776
|
|
G |
Uvrag |
UV radiation resistance associated |
decreases expression |
ISO |
Alitretinoin results in decreased expression of UVRAG mRNA |
CTD |
PMID:15982314 |
|
NCBI chr 1:153,185,356...153,442,200
Ensembl chr 1:153,185,395...153,442,136
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions affects activity increases degradation |
ISO |
[Alitretinoin co-treated with Calcitriol] results in increased stability of [RXRA protein binds to VDR protein]; Alitretinoin promotes the reaction [VDR protein binds to BGLAP gene] Alitretinoin affects the activity of VDR protein Alitretinoin results in increased degradation of VDR protein |
CTD |
PMID:12898515 PMID:16204233 PMID:16936639 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Alitretinoin results in increased expression of VEGFA mRNA |
CTD |
PMID:16386082 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
decreases expression |
ISO |
Alitretinoin results in decreased expression of VEGFC mRNA |
CTD |
PMID:15982314 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vim |
vimentin |
decreases expression multiple interactions |
ISO |
Alitretinoin results in decreased expression of VIM mRNA; Alitretinoin results in decreased expression of VIM protein [Tretinoin co-treated with Alitretinoin] results in decreased expression of VIM mRNA; Tretinoin promotes the reaction [Alitretinoin results in decreased expression of VIM protein] |
CTD |
PMID:28886987 PMID:31634547 PMID:36805303 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vipr1 |
vasoactive intestinal peptide receptor 1 |
multiple interactions |
ISO |
Alitretinoin inhibits the reaction [GW 4064 results in increased expression of VIPR1] |
CTD |
PMID:16037943 |
|
NCBI chr 8:121,303,739...121,339,587
Ensembl chr 8:121,310,248...121,339,585
|
|
G |
Wnt5b |
Wnt family member 5B |
decreases expression |
ISO |
Alitretinoin results in decreased expression of WNT5B mRNA |
CTD |
PMID:15972578 |
|
NCBI chr 4:152,609,566...152,733,790
Ensembl chr 4:152,609,569...152,733,407
|
|